Table 3.

Factors associated with overall survival and progression-free survival

Variable	Overall survival			Progression-free survival
	HR	95% CI	p	HR	95% CI	p
Gender  Female vs male	0.927	0.154–5.563	0.934	0.424	0.103–1.739	0.234
ECOG  0 vs 1	5.497	0.542–66.801	0.150	0.873	0.217–3.511	0.849
Histopathology  Adenocarcinoma vs SCC	0.087	0.005–1.393	0.084	0.232	0.024–2.250	0.208
Genetic mutation  EGFR vs ALK	0.580	0.015–39.800	0.277	2.003	0.243–260.278	0.657
Clinical stage  III vs IV	0.853	0.152–4.794	0.857	1.632	0.437–6.095	0.466
Preoperative stage  I/II vs III	3.205	0.582–17.663	0.181	4.377	1.083–17.691	0.038
ypStage  I/II/III vs IV	0.207	0.018–2.320	0.202	0.221	0.062–1.900	0.344
Indication for TKI  Neoadjuvant vs treatment	0.375	0.043–3.287	0.376	1.184	0.294–4.764	0.812
Indication for surgery  Regressed vs regrowth	0.086	0.008–0.957	0.046	0.299	0.054–1.652	0.166
Surgery  Lobectomy vs sublobectomy	0.348	0.031–3.853	0.289	0.904	0.179–4.566	0.903
Completeness resection  R0 vs R2	4.828	0.431–54.077	0.202	2.911	0.526–16.100	0.221
Postoperative TKI adjuvant  Yes vs no	0.506	0.099–2.587	0.413	0.146	0.027–0.782	0.025
Relapse  Yes vs no	6.268	0.701–825.479	0.259

ECOG Eastern Cooperative Oncology Group, EGFR epidermal growth factor receptor, ALK anaplastic lymphoma kinase, SCC squamous cell carcinoma, TKI tyrosine kinase inhibitor, HR hazard ratio, CI confidence interval